Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

HPV Serology and Circulating Viral DNA for Detection, Genotyping, and Measurement of Disease Burden in Oropharyngeal Cancer.

International journal of cancer·2026

Same author

Longitudinal validation of ENLIGHT, an AI predictor of immunotherapy response and resistance, in pan-cancer cohorts.

NPJ precision oncology·2026

Same author

Methylation-based ctDNA monitoring in metastatic breast cancer during CDK4/6 inhibitor therapy.

Nature communications·2026

Same author

Longitudinal evaluation of serial ctDNA kinetics using joint modeling in patients with metastatic breast cancer.

NPJ precision oncology·2026

Same author

CANLead: Canada as a Phase 1 Clinical Trial Leader - Opportunities, Initiatives, and Collaborative Innovation to Elevate National Competitiveness.

The oncologist·2026

Same author

Pan-Cancer Pre-Treatment ctDNA Detection Using a Highly Sensitive Tumor-Informed Assay.

International journal of molecular sciences·2026

Search research articles

Related Experiment Video

Updated: Jun 3, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Brivanib alaninate for cancer.

Ivan Diaz-Padilla¹, Lillian L Siu

¹Princess Margaret Hospital, Toronto, Ontario, M5G2M9 Canada. lillian.siu@uhn.on.ca

Expert Opinion on Investigational Drugs

|March 12, 2011

Summary

Brivanib, a dual tyrosine kinase inhibitor, shows tolerable safety and promising efficacy in treating hepatocellular carcinoma and colorectal cancer. Further studies are ongoing to evaluate its potential in other solid tumors and combinations.

Area of Science:

Oncology
Pharmacology
Molecular Biology

Background:

Angiogenesis inhibition is a key strategy for solid tumor treatment.
Brivanib is a dual tyrosine kinase inhibitor targeting VEGFR-2 and FGFR.

Purpose of the Study:

To review preclinical and clinical data of brivanib in cancer treatment.
To summarize brivanib's safety, efficacy, and pharmacokinetic/pharmacodynamic profiles.

Main Methods:

Literature review of published data up to December 2010.
Analysis of preclinical and clinical trial results presented in abstracts and journals.

Main Results:

Brivanib demonstrates a tolerable safety profile and favorable pharmacokinetics.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring

Published on: November 13, 2012

Related Experiment Videos

Last Updated: Jun 3, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring

Published on: November 13, 2012

Evidence of target inhibition in surrogate tissues supports brivanib's mechanism.

Oral administration of 800 mg once daily is supported by clinical data.

Conclusions:

Brivanib shows promise as a single agent in hepatocellular carcinoma.
Combination therapy with cetuximab demonstrates activity in colorectal cancer.
Ongoing trials are exploring brivanib with chemotherapy and in other solid tumors.